New England Journal of Medicine· 2012Q1

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

Gregory G. Schwartz, Anders Olsson, Markus Abt, Christie M. Ballantyne et al.

2,040citations
Q1SCImago
2012year

Short summary

Dalcetrapib, a CETP inhibitor, increased HDL cholesterol by 31-40% in patients post-acute coronary syndrome but failed to reduce the risk of major cardiovascular events over a median of 31 months.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine